The global sterilization process trend report unites insights from sterilization monitoring, terminal sterilization, medical instrument washing & disinfection, and sterile barrier systems markets. It highlights a growing shift toward automation, digital monitoring, and sustainable sterilizatio...Read More »
November 7, 2025
Insulin Lispro, marketed as Humalog by Eli Lilly, is one of the leading rapid-acting insulins used in the management of Type 1 and Type 2 diabetes. Its formulation provides a rapid onset of action, making it a preferred choice for patients needing quick postprandial glucose control. Humalog’...Read More »
November 6, 2025
Luspatercept (Reblozyl), co-developed by Acceleron Pharma and Bristol Myers Squibb, represents a transformative innovation in hematology as the first erythroid maturation agent (EMA) designed to address anemia associated with lower-risk myelodysplastic syndromes (MDS) and transfusion-dependent bet...Read More »
November 6, 2025
Retatrutide (LY-3437943), developed by Eli Lilly and Company, is an innovative triple agonist targeting the GLP-1, GIP, and glucagon receptors, engineered to deliver superior weight reduction and comprehensive metabolic benefits. By simultaneously enhancing insulin sensitivity, increasing energy e...Read More »
November 6, 2025
UST is a global digital transformation solutions provider. UST serves clients across industries with a focus on digital transformation, technology consulting, and managed services. UST operates in more than 30 countries worldwide. The company serves a range of industries including healthcare, fina...Read More »
November 5, 2025
Magnetic resonance imaging (MRI) has become a cornerstone in the evaluation and management of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), and other dementias. MRI provides a non-invasive, radiation-free method to...Read More »
November 5, 2025
Cerliponase alfa, marketed as Brineura by BioMarin Pharmaceutical, is an enzyme replacement therapy (ERT) developed for Neuronal Ceroid Lipofuscinosis Type 2 (CLN2), a rare lysosomal storage disorder. Since its approval in 2017, Brineura has represented a significant advancement in managing this f...Read More »
November 5, 2025
Nusinersen, marketed as Spinraza by Biogen, has significantly impacted the treatment landscape for spinal muscular atrophy (SMA), a rare and severe genetic disorder that leads to motor neuron degeneration. Spinraza's approval in 2016 marked a major milestone in SMA management, providing the first ...Read More »
November 4, 2025
Analyzing the pricing of dental membranes and bone graft substitutes is crucial for assessing market competitiveness, profit margins, and value positioning. It allows for the identification of key cost drivers, optimization of pricing strategies, and effective adaptation to market fluctuations. SK...Read More »
November 4, 2025
To provide a subscription-based monthly monitoring service that tracks key trends and developments in the durable medical equipment market, including product approvals, HCPCS code updates, indication changes, FDA submission and approval timelines, and evolving market trends. The subscription can b...Read More »
November 4, 2025
Implantable glucose sensors represent the future of diabetes monitoring. They can be considered a long-lasting, fully implanted option that supersedes the need for both fingerstick blood glucose monitoring (BGM) and short-wear transcutaneous continuous glucose monitors (CGMs). The insertion of the...Read More »
November 3, 2025
Nipocalimab (Imaavy), developed by Johnson & Johnson’s Janssen Pharmaceuticals, represents a groundbreaking advancement in the field of immunology as a first-in-class neonatal Fc receptor (FcRn) antagonist. Designed to selectively block IgG recycling, it offers precise modulation of auto...Read More »
November 3, 2025
Dental implants are crucial in modern dentistry as they provide a durable and natural-looking solution for tooth replacement, improving oral functionality, aesthetics, and patient quality of life. The market is led by major players such as Dentsply Sirona, Institut Straumann AG, Nobel Biocare (Env...Read More »
November 3, 2025
Pegozafermin (BIO89-100), developed by 89bio, Inc., is an advanced glycoPEGylated fibroblast growth factor 21 (FGF21) analog designed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). By enhancing insulin sensitivity, promoting lipid metabolism, and r...Read More »
November 3, 2025
Depemokimab (GSK3511294), developed by GlaxoSmithKline, is an innovative ultra–long-acting monoclonal antibody targeting interleukin-5 (IL-5) for the treatment of severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), conditions driven by Type-2 inflammation affect...Read More »
November 3, 2025
The 3D and 4D-printed dental implants transform restorative dentistry by enabling patient-specific, high-precision implants with enhanced osseointegration and mechanical performance. Key drivers include the rising demand for personalized treatments, advancements in biocompatible materials, and int...Read More »
October 31, 2025
The bone and joint health supplements market is entering a new phase of evolution, shaped by preventive healthcare trends, functional nutrition, and shifting consumer demographics. While North America and Western Europe remain mature markets with high brand penetration, emerging regions such as As...Read More »
October 30, 2025
Vosevi, a combination therapy of Sofosbuvir, Velpatasvir, and Voxilaprevir, developed by Gilead Sciences, has played a pivotal role in the treatment of chronic hepatitis C. Its high efficacy across all six genotypes of the virus has contributed to its success in the antiviral market. As the patent...Read More »
October 30, 2025
The carrier screening market is experiencing significant growth, driven by the rising incidence of genetic disorders such as cystic fibrosis, sickle cell disease (SCD), and Tay-Sachs disease. There are nearly 10,000 known single-gene disorders, also called monogenic disorders, resulting from mutat...Read More »
October 29, 2025
Edoxaban, marketed as Savaysa and Lixiana, is an oral, selective factor Xa inhibitor developed by Daiichi Sankyo that has transformed anticoagulation therapy for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. Approved in more than 40 countries, it offers convenie...Read More »
October 29, 2025